Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 29;11:558894. doi: 10.3389/fphar.2020.558894

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Wong, Lewies, Haigh, Viljoen, Wentzel, Haynes and du Plessis

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Efficacies of amino-artemisinins against normal keratinocytes (HaCat) and melanoma cells (A375). (A) Dose-response curves of geranylpiperazine-DHA 6 and farnesylpiperazine-DHA 7 (top panel) and their respective combinations with elesclomol-Cu(II) 1-Cu (bottom panel) determined with the MTT assay. (B) The fraction effected (Fa) vs the combination index (CI) plot for drug combinations at constant drug ratios. The dashed line indicates an additive effect, data points below 1 indicates synergism. (C) The effect of different concentrations of geranylpiperazine-DHA 6 and farnesylpiperazine-DHA 7 and their combinations with elesclomol-Cu(II) 1-Cu on membrane integrity determined with the LDH assay. Results are presented as mean ± SD, n=3. *Denotes statistical difference from the control.